Originally developed in 2009 by Pfizer with the intention to be tested for analgesic properties, MAB-CHMINACA soon proved to have other features that appeal to advanced researchers. According to the results of initial observations, the substance displays very high affinity for CB1 receptors at 0.289 nM, which is considerably above values measured for some of the conventional synthetic cannabinoids. New product is structurally related to several other indazole-based chemicals including AB-FUMINACA and AB-CHMINACA, but is unique because of a tert-butyl group substituting the isobutyl moiety in the molecular chain. Due to its novelty, little is presently known about the physical and chemical properties of MAB-CHMINACA, and its pharmacological profile will have to be mapped by quantitative research.
RCNET-Chemicals is a reliable source of MAB-CHMINACA of very high purity, with guaranteed delivery to specified address anywhere in the world. Please note that local restrictions or regulations could apply to this chemical and verify its current legal status before placing an order. The product may only be used for controlled scientific research under strict supervision of qualified laboratory personnel and is not approved for pharmaceutical or veterinary purposes. Any kind of application outside of in vitro experiments represents a breach of our policies and could have potentially hazardous consequences.
Per our standard policy, MAB-CHMINACA and other chemical products in catalogue are approved exclusively as forensic materials for in vitro analysis. Any other use is strictly prohibited and any kind of contact between the chemicals and living organisms should be avoided at all costs. It is possible that MAB-CHMINACA is a restricted substance in some jurisdictions and buyers are required to meet all local laws and regulations in regards to research materials ordered from our online store.